# Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults

> **NCT04911790** · PHASE4 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 131650 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Experimental Group

## Key facts

- **NCT ID:** NCT04911790
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-05
- **Primary completion:** 2023-01-02
- **Final completion:** 2023-08-31
- **Target enrollment:** 131650 (ACTUAL)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911790, "Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04911790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*